Liposomal chemotherapy in cutaneous T-cell lymphomas: current status and future prospects
U. Wollina
From the Department of Dermatology & Allergology, Hospital Dresden-Friedrichstadt, Academic Teaching Hospital of the Technical University of Dresden,
Friedrichstrasse Dresden, Germany
Liposomes are lamellar structures composed of a lipid bilayer. They are used as carriers for different drugs. The present paper reviews the use of intravenous liposomal anticancer drugs in dermato-oncology. The broadest application is found today for liposomal anthracyclines, i.e. doxorubicin and daunorubicin. There is clear evidence for liposomal drug efficacy and safety cutaneous T-cell lymphoma (CTCL) with response rates about 80-90%. Randomized, double-blinded prospective controlled trials are on the way.
[>Read full article in PDF]